Counting down the Top 3 Drug Searches on @drugdocs.bsky.social in 2025.

#3: YERVOY® (ipilimumab). In 2025, FDA approved nivolumab + ipilimumab for MSI-H/dMMR metastatic CRC and unresectable/metastatic HCC.

💊 Find the clinical evidence for #Yervoy at: drugdocs.com/drug/Yervoy
#Oncology #DRUGDOCS

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #ImmuneCheckpointInhibitor #Immunotherapy #Keytruda #Opdivo #Yervoy #Imfinzi #Jemperli #Vocabulary

BMS granted FDA approval for immunotherapy combination in colorectal cancer - PMLiVE More than 154,000 cases of the disease are expected to be diagnosed in the US this year

#FDAapproval #immunotherapy #colorectalcancer #BristolMyersSquibb #Opdivo #Yervoy #OpdivoplusYervoy #nivolumabplusipilimumab #MSIHcolorectalcancer #dMMRcolorectalcancer #dMMRtumours #MSIHtumours #FDAacceleratedapprovalspathway #CheckMate8HWtrial
pmlive.com/pharma_news/...

The Growth and Future of CTLA-4 Inhibitors in Cancer Treatment: 2020-2034 CTLA-4 inhibitors are projected to witness significant growth due to increased cancer prevalence and innovative therapies. Explore the market insights.

The Growth and Future of CTLA-4 Inhibitors in Cancer Treatment: 2020-2034 #United_States #Las_Vegas #CTLA-4_inhibitors #YERVOY #IMJUDO

More granular data from CHECKMATE 9DW in #HCC
😊 ORR 36% for #Opdivo+#Yervoy vs. 13% for LEN/SOR
🙁 CR 7% vs. 2%
🙂 median duration of response 30.4 months vs. 12.9 months
☹️ TRAEs of any grade in 84% ICI vs. 91% LEN/SOR
☹️ Grade 3/4 TRAEs in 41% and 42%
#livertwitter

@AASLDtweets clearly the era of combo systemic Rx for #HCC has been ushered with #tecentriq + #avastin , #keytruda + #lenvima and now #Opdivo +#yervoy looming at the horizon. I definitely foresee an HCC centric #livermtg20 #LiverMtg19

#FDA Accepts for Priority Review $BMS Application for #Opdivo + #Yervoy in 2L for #HCC...